Live Breaking News & Updates on Fundacion Jimenez Diaz
Stay updated with breaking news from Fundacion jimenez diaz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bernard Doger de Spéville, MD, PhD, discusses the investigation of eftilagimod alpha plus pembrolizumab in the TACTI-002 trial, including prior evidence supporting this approach, the trial’s design and primary objective, and the combination’s efficacy and safety in both the head and neck squamous cell carcinoma and non–small cell lung cancer cohorts. ....
Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma. ....
An analysis of postmortem records showed fewer suicides among individuals with schizophrenia who were taking clozapine, an underutilized antipsychotic, compared to those taking other antipsychotics. ....
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) and Pulmatrix (NASDAQ:PULM – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Valuation and Earnings This table compares Rocket Pharmaceuticals and Pulmatrix’s […] ....
Eyenovia (NASDAQ:EYEN – Get Rating) and Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. Volatility & Risk Eyenovia has a beta of 2.08, indicating […] ....